The DNA methylome is a rich source of information about human disease. Adela’s genome-wide methylome enrichment platform uniquely captures information efficiently from the entire methylome.
Adela’s technology distinguishes the most-highly informative (methylated) regions of the genome from non-informative regions and preferentially targets those regions for sequencing.
In addition, Adela’s technology does not require bisulfite conversion, which is a chemical treatment that causes loss of valuable genomic material and information.
Adela's technology leverages machine learning to detect and classify underlying disease, including tissue of origin and histologic subtype.
Adela, Inc. announced today that it will present data demonstrating the ability of its genome-wide methylome enrichment platform to detect multiple types of cancer at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023.
Daniel De Carvalho, PhD will deliver a plenary session titled “Cancer Early Detection, Classification and Monitoring using Plasma Cell-Free DNA Methylomes” at the AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer on November 18, 2022.
Adela, Inc., focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test, has enrolled the first participant in a multi-center study supporting the development and validation of its genome-wide methylome enrichment platform for the early detection of cancer.
Adela, Inc., focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test, has made appointments to the Executive Team and Board of Directors that add to the deep industry and scientific expertise of the current team. The company has also formed a Scientific Advisory Board comprised of renowned scientists and clinicians.
Adela’s technology detects signals of early disease with high sensitivity through efficient mining of the entire methylome
New Haven · Toronto · San Francisco
